Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study
Abstract
AIMS: Dapagliflozin and sitagliptin exhibit variable efficacy in managing type 2 diabetes mellitus (T2DM), with outcomes influenced by factors like body mass index (BMI). However, biochemical determinants of treatment response remain poorly defined. This study aimed to determine whether baseline alanine aminotransferase (ALT) levels can independently predict differential responses to these drugs.
MATERIALS AND METHODS: This post hoc analysis of the Dapagliflozin Versus Sitagliptin for Type 2 Diabetes-Cardiovascular Risk (DIVERSITY-CVR) study, a randomized, open-label trial in Japan, included 340 patients with T2DM on metformin monotherapy or no treatment. Analysis of variance and regression analyses were conducted, adjusting for allocation factors (glycated haemoglobin [HbA1c] ≥//≤ 0.5 g/day). Three models (M1-M3) included baseline HbA1c, BMI and/or allocation adjustment factors. Co-primary endpoints were HbA1c and time in range.
RESULTS: Baseline ALT levels were significantly associated with changes in HbA1c and time in range at 24 weeks. Patients with lower ALT showed better response to sitagliptin, while those with higher ALT exhibited enhanced efficacy with dapagliflozin across all models (p < 0.05). Regression analysis revealed significant interactions between ALT, BMI and HbA1c (p = 0.02, 0.03). A significant correlation between baseline ALT and HbA1c change was observed in the total cohort (p = 0.03) and sitagliptin group (p < 0.01).
CONCLUSIONS: Baseline ALT is a…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 340 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.